IL6 and breast carcinoma: In breast cancer, Hu et al. [58] demonstrated that IL6 derived from CAFs could differentiate into regulatory T cells (Treg) through the IL6/STAT3 pathway, that is, CD73(+) gamma delta Tregs, which has a more powerful immunosuppressive effect and promoted tumor progression.